As shown in Fig. 1b and Supplementary Fig. 1c, cell survival similarly decreased in a dose-dependent manner 72 h after sempervirine treatment for each tumor cell type, irrespective of cisplatin sensitivity or p53 status. Here, TP53 is linked to neoplasm.